Clinical efficacy and tolerability of infliximab in patients with severe ankylosing spondylitis

Мukhammadievа S.М., Nabievа D.A., Abduazizova N.X., Xidoyatova M.R.

dc.contributor.author	Мukhammadievа S.М., Nabievа D.A., Abduazizova N.X., Xidoyatova M.R.
dc.date.accessioned	2023-01-19T10:19:46Z
dc.date.available	2023-01-19T10:19:46Z
dc.date.issued	2022-12
dc.identifier.issn	2729-8043
dc.identifier.uri	http://repository.tma.uz/xmlui/handle/1/5892
dc.description.abstract	This article is devoted to the effectiveness of the treatment of ankylosing spondylitis (AS), one of the chronic inflammatory disease of the musculoskeletal system. The study included 53 patients with active AS (BASDAI activity index >4) and failure of standard therapy, which included the TNF-a inhibitor infliximab (INF) at a dose of 3-5 mg/kg intravenously for 0, 2, 6 weeks and next every 8 weeks. In patients treated with INF, a positive clinical effect was achieved by indicators BASDAI and BASMI scores, as well as a remarkable positive result in dynamics vertebral mobility index and BASFI score. Tolerability of INF patients was satisfactory.	en_US
dc.language.iso	en	en_US
dc.publisher	Switzerland	en_US
dc.subject	ankylosing spondylitis, diagnosis, treatment, TNF-α inhibitors, infliximab.	en_US
dc.title	Clinical efficacy and tolerability of infliximab in patients with severe ankylosing spondylitis	en_US
dc.type	Article	en_US